Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2020 Dec;35(Suppl 3):972-977.
doi: 10.1007/s11606-020-06254-7. Epub 2020 Nov 3.

Promoting Patient-Centeredness in Opioid Deprescribing: a Blueprint for De-implementation Science

Affiliations
Editorial

Promoting Patient-Centeredness in Opioid Deprescribing: a Blueprint for De-implementation Science

Stefan G Kertesz et al. J Gen Intern Med. 2020 Dec.

Abstract

A downward trend in opioid prescribing between 2011 and 2018 has brought per-capita opioid prescriptions below the levels of 2006, the earliest year for which the Centers for Disease Control and Prevention has published data. That trend has affected roughly ten million patients who previously received long-term opioid therapy. Any effort to reduce or replace a prior health practice is termed de-implementation. We suggest that the evaluation of opioid prescribing de-implementation has been misdirected, within US policy and health research, resulting in detrimental impacts on patients, their families and clinicians. Policymakers and implementation scientists can address these deficiencies in how we study and how we perform opioid de-implementation by applying an implementation science framework: the Consolidated Framework for Implementation Research. The Consolidated Framework lays out relevant domains of activity (internal, external, etc.) that influence implementation processes and outcomes. It can deepen our understanding of how policies are chosen, communicated, and carried out. Policymakers and researchers who embrace this framework will need a better approach to measuring success and failure in health care where both pain and opioids are concerned. This would involve shifting from a reductive focus on opioid prescription counts toward measures that are more effective, holistic, and patient-centered.

PubMed Disclaimer

Conflict of interest statement

Dr. Kertesz affirms past personal ownership of stock in Merck and Abbott pharmaceutical companies, sold in December of 2017, and not exceeding 5% of his assets at the time. Dr. Kertesz holds stock in CVS Caremark, Thermo Fisher, and Zimmer Biomet, not exceeding 5% of his assets. Dr. Kertesz reports his spouse holds equity in Merck, Abbot, Thermo Fisher, and Johnson and Johnson, in her private assets, not exceeding 10% of her assets. Dr. Kertesz receives income from UpToDate, Inc. Dr. Darnall is the recipient of a research award from the Patient-Centered Outcomes Research Institute® (#1610-3700), author royalties from multiple books, and compensation as chief scientific advisor at AppliedVR. Dr. Varley receives part-time income from Heart Rhythm Clinical and Research Solutions.

Figures

Fig. 1
Fig. 1
The figure offers selected examples of actors and agencies that, collectively, influence opioid prescribing in the USA, grouped into the following domains: “Governmental,” “Guidelines and Metrics,” “Framing Voices,” and “Providers and Payers.” The four domains are offered with illustrative intent and are not necessarily exhaustive or mutually exclusive. For example, a government agency may produce a guideline and also influence how the guideline is understood through collaboration with a journalist (i.e., a Framing Voice). CMS, The Centers for Medicare & Medicaid Services; CDC, Centers for Disease Control and Prevention; DEA, Drug Enforcement Agency; VA, Department of Veteran Affair’s; DoD, Department of Defense; NCQA, National Committee for Quality Assurance.

References

    1. Frieden TR, Houry D. Reducing the risks of relief--the CDC Opioid-Prescribing Guideline. N Engl J Med. 2016;374(16):1501–1504. - PMC - PubMed
    1. CDC National Center for Injury Prevention and Control. 2019 Annual Surveillance Report of Drug-Related Risks and Outcomes — United States Surveillance Special Report. Centers for Disease Control and Prevention, U.S. Department of Health and Human Services. Published November 1, 2019. Available at: https://www.cdc.gov/drugoverdose/pdf/pubs/2019-cdc-drug-surveillance-rep.... Accessed January 24, 2020.
    1. Bohnert ASB, Guy GP, Jr, Losby JL. Opioid prescribing in the United States before and after the Centers for Disease Control and Prevention’s 2016 Opioid Guideline. Ann Intern Med. 2018;169(6):367–375. - PMC - PubMed
    1. Norton WE, Chambers DA. Unpacking the complexities of de-implementing inappropriate health interventions. Implement Sci. 2020;15(1):2. - PMC - PubMed
    1. Rubin R. Limits on opioid prescribing leave patients with chronic pain vulnerable. JAMA. 2019;321(21):2059–2062. - PubMed

Publication types

Substances

LinkOut - more resources